Ask AI
ProCE Banner Activity

DURGA-1: Phase Ib/II Study of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-Cell Therapy, in R/R MM

Conference Coverage
Slideset

Preliminary data from the phase Ib/II DURGA-1 trial suggest that AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, demonstrated a manageable safety profile and promising efficacy among patients with heavily pretreated relapsed/refractory multiple myeloma with reliable manufacturing time and outpatient administration potential. 

Released: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for healthcare professionals who care for patients with malignant or nonmalignant hematologic disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with malignant or nonmalignant hematologic disorders

  • Evaluate new data on novel agents and therapeutic approaches for patients with malignant or nonmalignant hematologic disorders

  • Appraise how new trial findings might advance the treatment of patients with malignant or nonmalignant hematologic disorders in the future

  • Support informed shared decision-making for patients with malignant and nonmalignant hematologic disorders through accessible discussion of the potential clinical implications of recently presented data